Fig. 12: Anti-tumor recurrence effects of systemic administration of PTX and siVEGF co-delivery using the ADENS in A375 tumor-bearing mice. | NPG Asia Materials

Fig. 12: Anti-tumor recurrence effects of systemic administration of PTX and siVEGF co-delivery using the ADENS in A375 tumor-bearing mice.

From: Amphiphilic dendrimer engineered nanocarrier systems for co-delivery of siRNA and paclitaxel to matrix metalloproteinase-rich tumors for synergistic therapy

Fig. 12

a Tumor growth curves. The arrow denotes the time of drug administration. All results are presented as the means ± SD (n = 6). b Kaplan–Meier survival plot. c VEGF mRNA expression in tumor tissues. All results are presented as the means ± SD (n = 3). d Immunohistochemical images of representative tumor tissues stained with CD31 antibody. The doses of siRNA and PTX were 1 mg/kg and 3 mg/kg, respectively. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page